Reuters logo
3 months ago
BRIEF-Evoke Pharma presents Gimoti efficacy and safety data from phase 3 trial
May 10, 2017 / 1:50 PM / 3 months ago

BRIEF-Evoke Pharma presents Gimoti efficacy and safety data from phase 3 trial

1 Min Read

May 10 (Reuters) - Evoke Pharma Inc:

* Evoke Pharma presents Gimoti efficacy and safety data from phase 3 trial as late breaker at digestive disease week 2017

* Says safety data from phase 3 trial were consistent with favorable results from previous gimoti studies

* Evoke Pharma - based on recent fda discussions, these data are anticipated to be submitted as part of a new drug application for Gimoti

* Says trial data was not statistically significant in itt group

* Evoke Pharma - patients, which 51pct enrolled in study, responded clinically and statistically significantly better to gimoti than placebo Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below